Latest Breaking News On - Structural heart - Page 10 : comparemela.com

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

Ryan weispfenningRachel murrayRossj jrJeffrey popmaExchange commissionOur missionRenal denervationStructural heartCardiovascular portfolioCommercial experienceAortic stenosisNited states food and drug administrationCoronary arteriesAortic valve replacement